Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency

Agnieszka Butwicka · Szymańska Krystyna · Włodzimierz Retka · Tomasz Wolańczyk

Abstract We describe a patient with dystonia and psychotic symptoms treated with standard doses of antipsychotics, who developed neuroleptic malignant syndrome (NMS). A 16-year-old male with a history of misuse of dextromethorphan and pseudoephedrine for recreational purpose presented with dystonia and a psychotic episode. Following continuous treatment with olanzapine (10 mg/day), repeated injections of levomepromazine (37.5 mg/day), and a single injection of haloperidol (2.5 mg), the patient developed NMS. Muscular rigidity, fever (up to 41 °C), hypotension (100/70 mmHg), tachycardia (120 beats per minute), tachypnea (26 breaths per minute), elevated leukocyte count (up to 16.6×10³/μL), and elevated serum creatinine phosphokinase (CPK) (up to 15,255 U/L) were observed. A diagnosis of NMS was made according to the DSM-IV TR criteria. Genotyping revealed that he was homozygous for a non-functional CYP2D6*4 allele. The case highlights the importance of therapeutic drug monitoring in identification and differentiation of drug-induced effects in psychiatric disorder to prevent NMS and its complications. In addition, genotyping of CYP2D6 might be considered in patients with symptoms suggestive of drug toxicity who are treated with neuroleptics metabolized via the CYP2D6 pathway, as carriage of one or more non-functional alleles may increase the risk for adverse reactions, such as NMS.

Keywords Adverse drug reactions · Pharmacogenetics · CYP2D6 · Poor metabolizer · Neuroleptic malignant syndrome

Abbreviations

BUN Blood urea nitrogen
CPK Serum creatinine phosphokinase
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
TR Disorders, Fourth Edition, Text Revision
EEG Electroencephalography
ICU Intensive care unit
NMS Neuroleptic malignant syndrome
PCR Polymerase chain reaction
SCC Creatinine
TDM Therapeutic drug monitoring
WBC Leukocyte count

Introduction

The use of atypical antipsychotic has increased rapidly in recent years in pediatric populations worldwide [1]. Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication of treatment with antipsychotics. Clinical features of NMS include muscle rigidity, hyperpyrexia, autonomic instability, mental status changes, and evidence of muscle catabolism [2]. One of the hypotheses regarding its etiology postulates that susceptibility to NMS may be associated with variation in genes that code for metabolic enzymes [7]. We report on a pediatric patient who developed NMS while being treated with standard doses of antipsychotics due to an acute psychotic episode. Clinical observation suggested drug toxicity due to impaired drug metabolism. Genotyping of
the CYP2D6 gene confirmed the carriage of two dysfunctional alleles.

Case report

In September 2009, a 16-year-old male (weight: 65.5 kg, height: 1.83 m, BMI=19.6 kg/m²) was admitted to a pediatric neurology unit due to dystonia. A month before, the patient became withdrawn and developed insomnia and twisting movements of the left extremities. These symptoms began after a 1-month period of using medication containing dextromethorphan and pseudoephedrine for recreational purpose. Upon admission to the pediatric neurology unit, he was well oriented and followed instructions. Neurological examination showed no alteration except for sustained twisting of the left extremities. Results of laboratory tests, electroencephalography (EEG), and computed tomography of the head and neck were normal. During hospitalization his mental status deteriorated. He became confused and illogical. The consulting psychiatrist diagnosed a psychotic episode and transferred the patient to the adolescent inpatient psychiatric unit.

At the time of this transfer, the patient was awake and revealed delusional thoughts and hallucinations. Treatment with orally administered olanzapine (10 mg/day) and lorazepam (as required) with intramuscular injections of first-generation antipsychotic medication—levomepromazine (25 mg/day)—was initiated. The next day, levomepromazine was increased to 37.5 mg/day. During the course of treatment, dystonic movement worsened. Opisthotonic trunk extension, intermittent, sustained extension movements of the arms, and incomprehensible screaming were observed. The patient had no verbal communication with the medical staff, was agitated, unable to sleep, and refused to eat and drink. Intravenous fluids were administered for dehydration. In 2 weeks of treatment, he became drowsy with decreased physical activity. Due to recurrent episodes of agitation, the patient received 1–3 mg/day of lorazepam. An episode of aggression towards medical staff required one intramuscular injection with haloperidol (2.5 mg). The timeline of presented symptoms and administered medications is displayed in Fig. 1. At the 16th day of treatment with antipsychotics, the patient was transferred to the University Child Psychiatry Department.

At the time of this transfer, the patient was unconscious and showed muscular rigidity and extrapyramidal symptoms. Fever (up to 41 °C), hypotension (100/70 mmHg), tachycardia (120 beats per minute), and tachypnea (26 breaths per minute) were noted. Laboratory analysis revealed a leukocyte count (WBC) of 13.40×10³/μL, serum creatinine phosphokinase (CPK) level of 639 U/L, and normal liver and renal function tests.

On the following day, the patient became diaphoretic, with a Glasgow Coma Scale of 7 points (range 3–15 points) indicating a state of coma. CPK increased to 2,458 U/L, WBC to 16.6×10³/μL, creatinine (SCC) to 1.70 mg/dL, and blood urea nitrogen (BUN) to 79.0 mg/dL. The patient was transferred to an intensive care unit (ICU), intubated and mechanically ventilated because of respiratory insufficiency. Generalized tonic-clonic seizures were observed. Acyclovir was administered for potential herpes encephalitis and dantrolene to

![Timeline of presented symptoms and administered medication prior to admission to the intensive care unit](image-url)
counter potential NMS. Electrocardiogram revealed elevation of the ST segment with T wave inversion. Elevated troponin levels and myoglobin detected in urine suggested myocardial injury. An echocardiogram showed left ventricular hypokinesis. Serum CPK levels continued to rise over the following 6 days and reached a peak of 15,255 U/L. BUN and SCC also increased for 3 days, up to 79.6 and 2.1 mg/dL, respectively. Organic pathology of the brain was ruled out after repeatedly normal magnetic resonance images and cerebrospinal fluid examination (glucose concentration 70.0 mg/dL, protein concentration 34 mg/dL, and an absence of cells). Polymerase chain reaction (PCR) ruled out herpes simplex virus infection, and acyclovir was discontinued. Six weeks after the last administration of neuroleptics, urine toxicology was done. The presence of haloperidol was detected, but not olanzapine. The presence of levomepromazine was not measured. There was no test performed to measure any plasma drug concentration. Real-time PCR showed that the genotype of CYP2D6 was *4/*4. These findings indicated lack of drug concentration. Sometime after the patient was discharged, and no other medications were required. In September 2010, he was discharged from inpatient center with diagnosis of catatonia, suggests drug toxicity. Metabolism of levomepromazine and haloperidol is catalyzed by CYP2D6 and it's combination with levomepromazine in the development of NMS has been previously described [5, 8]. The plasma level of olanzapine should not have exceed therapeutic levels as it is mainly metabolized by CYP1A2 and to a lesser extent by CYP2D6. However, the clinical presentation, with the lack of improvement and sedation on adequate doses of medications combined with worseness of catatonia, suggests drug toxicity. Metabolism of levomepromazine and haloperidol is catalyzed by CYP2D6 and if given to the patient with lack activity of this enzyme might have induced adverse effects even on standard doses [3]. Furthermore, nonfunctional allelic of CYP2D6 have been suggested to affect vulnerability to NMS in Japanese population [6]. Other factors such as dehydration, malnutrition, and severe clinical presentation with agitation may also contribute to the development of NMS. Initial symptoms of the patient might be also related to the abuse of dextromethorphan- and pseudopepdrine-containing remedies as both medications are metabolized by CYP2D6 and known to cause dystonia and psychotic symptoms [10].

Our report highlights the need for therapeutic drug monitoring (TDM) [4]. TDM is economically reasonable and can detect different pharmacokinetic problems, not limited to CYP polymorphisms. Unfortunately, in Poland, TDM of neuroleptics was not implemented in the clinical routine and even if recommend remains unavailable in psychiatric centers. Described patient had several indications for measuring plasma concentration of medication such as possible medication-related onset of symptoms, adverse effects on standard doses of medication, suspected impaired drug metabolism, and being an adolescent patient. Plasma levels of drugs involved in this case would have been helpful to evaluate the origin of symptoms, modify the treatment, and avoid dramatic complication.
Acknowledgments  We thank Dr. Sameer Jauhar from the Institute of Psychiatry, King’s College London for his constructive comments and proofreading.

Conflict of interest  We report no conflict of interest.

Open Access  This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Clavenna A, Rossi E, DeRosa M, Bonati M (2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 166(4):339–347. doi:10.1007/s00431-006-0244-7
2. Croarkin PE, Emslie GJ, Mayes TL (2008) Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 69(7):1157–1165
3. Fang J, Baker GB, Silverstone PH, Couts RT (1997) Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17(2):227–233
4. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Stiot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MI, Pfuhrmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschglr R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195–235. doi:10.1055/s-0031-1286287
5. Jarventausta K, Leinonen E (2000) Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand 102(3):231–233
6. Kato D, Kawanishi C, Kishida I, Furuno T, Suzuki K, Onishi H, Hirayasu Y (2007) Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 63(11):991–996. doi:10.1007/s00228-007-0355-8
7. Kishida I, Kawanishi C, Furuno T, Kato D, Ishigami T, Kosaka K (2004) Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene. Mol Psychiatry 9(3):293–298. doi:10.1038/sj.mp.4001422
8. Kontaxakis VP, Havaki-Kontaxaki BJ, Christodoulou NG, Paplos KG (2002) Olanzapine-associated neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry 26(5):897–902
9. Luchini F, Lattanzi L, Bartolommei N, Cosentino L, Litta A, Kansky C, Mauri M, Cassano GB, Fagiolini A, Casamassima F (2013) Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports. J Nerv Ment Dis 201(1):36–42. doi:10.1097/NMD.0b013e31827a24b
10. Soutullo CA, Cottingham EM, Keck PE Jr (1999) Psychosis associated with pseudoephedrine and dextromethorphan. J Am Acad Child Adolesc Psychiatry 38(12):1471–1472. doi:10.1097/00004583-199912000-00004
11. van Maidegem BT, Smit LME, Touw DJ, Gemke RBJ (2002) Neuroleptic malignant syndrome in a 4-year-old girl associated with alimemazine. Eur J Pediatr 161(5):259–261. doi:10.1007/s00431-002-0956-2